Metrion Biosciences Enhances High Throughput Screening Services With Access to Enamine Compound Libraries
Metrion Biosciences Closes £3.7m New Equity Financing
Metrion Biosciences Announces Launch of Good Laboratory Practice (GLP) hERG Screening Service
Metrion Biosciences Limited, a specialist ion channel contract research and drug discovery company, has received notification from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) that it is now a member of the UK GLP (Good Laboratory Practice) compliance monitoring program and is therefore able to offer GLP compliant hERG ion channel screening services to the global life sciences community.
Metrion Biosciences Limited, an ion channel contract research and drug discovery company, appointed Robert Kirby chief operating officer and Edward Stevens chief scientific officer.
CAMBRIDGE, England--(BUSINESS WIRE)--Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointments of Dr Robert Kirby to Chief Operating Officer and Dr Edward Stevens to Chief Scientific Officer. Both appointments represent promotions from within the company.
Metrion Biosciences and The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder
CAMBRIDGE, England--(BUSINESS WIRE)--Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Benedetta Montagnini as Head of European Business Development. Driven by the uptake of its ion channel discovery services, the appointment follows the recent creation of a Client Services team as Metrion expands its operations and enhanced drug discovery capabilities, internationally.
CAMBRIDGE, England & BRUSSELS--(BUSINESS WIRE)--Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, and Bioqube Ventures (“Bioqube”), a specialist European life sciences investment firm, announced today that they have entered into a collaboration, backed by Bioqube Factory Fund I, to incubate a drug discovery research project targeting autoimmune diseases.
Metrion Biosciences Limited, a specialist ion channel contract research and Drug Discoveryncompany, has expanded its capabilities and expertise through the naddition of automated low volume liquid handling capability and 384-wellnelectrophysiology and fluorescence-based high throughput screening ( HTS ) Assay systems.